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B Y COINCIDENCE, reserpine, which is the oldest and weakest, and guanethidine, which is the 
latest and most potent of the modern antihy- 
pertensive drugs, share a common basic pharma- 
cologic action. Both agents lead to depletion of 
the body stores of norepinephrine and thus, to 
varying degrees, interference with the function 
of the sympathetic nervous system.1-4 The 
precise mechanism by which they prevent the 
storage of norepinephrine is unknown, but evi- 
dence for its immediate release is seen in the 
transient rise in blood pressure and cardiac out- 
put after intravenous injection of guanethidineP 
Reserpine produces no such acute changes in 
man, but a similar release has been observed in 
animal preparations.“z6 
Since both these agents lead to depletion of 
the sympathetic transmitter substance, the 
vascular smooth muscle retains its responsiveness 
to norepinephrine; indeed, an increased sensi- 
tivity is observed. The pressor effect of certain 
vasoconstrictor drugs, however, is diminished. 
These drugs-such as tyramine, amphetamine 
and ephedrine-depend for their action upon 
the presence of stored catecholamines in the 
tissue.? -g 
While guanethidine and reserpine share a 
similar mode of action, some important differ- 
ences in their pharmacologic properties must 
be recognized. Guanethidine appears to pro- 
duce actual blockade of adrenergic neurones in 
addition to depleting catecholamines. It does 
not cross the blood-brain barrier; hence its effects 
are confined to the peripheral sympathetic 
nervous system. Furthermore, in contrast to 
reserpine, it does not result in depletion of the 
catecholamine content of the adrenal medulla.1° 
Reserpine, on the other hand, crosses the blood- 
brain barrier and depletes cerebral stores of 
norepinephrine” as well as those of hydroxy- 
tryptamine (serotinin).tZ To this may be at- 
tributed its sedative and psychologic and cer- 
tain endocrine effects.‘” 
Therefore it was originally believed that the 
site of action of reserpine was a central one, 
probably in the l~ypothalamus.‘4 However, 
the observation that at lower doses of reserpine 
the peripheral stores of norepinephrine are more 
depleted than the central onesI has led to the 
conclusion that, as far as its hypotensive action 
is concerned, the main site of action of reserpine 
might be a peripheral one. 
While the pharmacologic mode of action of 
reserpine and guanethidine tend to be similar, 
their clinical effects are conspicuous by con- 
trasts rather than by comparisons. 
RESERPINE : CLINICAL EFFECTS 
Reserpine is a mild antihypertensive agent. 
In oral doses of 0.8 to 1.5 mg./day a reduction 
of approximately 17/11 mm. Hg in blood pres- 
sure has been found in two controlled double- 
blind studies.t6,t7 Both the recumbent and 
standing pressures are affected without reduction 
in cardiac output,‘” renal blood flow, glomerular 
filtration ratelg or cerebral blood Aow.~O The 
reduction in pressure progresses slowly over a 
period of weeks and persists for a similar period 
after the drug has been discontinued. 
The side Pffects of reserpine (Table I), although 
few and comparatively infrequent, are nonethe- 
less serious since their gradual onset may delay 
detection; mental depression has been severe 
enough to result in suicide. Consequently, it 
is recommended that the maximal oral dose for 
long-term therapy should be limited to 0.5 
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TABLE I 
Side Effects of Reserpine 
Nasal stuffiness 
Increased appetite and weight gain 
Fluid retention 
Increased gastric acidity with possible 
aggravation of peptic ulcer 
Diarrhea 





mg.,/day. The reduced antihypertensive effect 
of the smaller dose can to some extent be offset 
by simultaneous use of a diuretic agent. 
Clinical A@lication: Reserpine therefore can 
be recommended for the milder cases of hyper- 
tension in which the diastolic pressure does not 
exceed 105 mm. Hg. Oddly enough, parenteral 
reserpine (1-3 mg. intramuscularly) can be 
recommended in emergencies. The gradual 
fall in pressure over a period of 3 to 4 hours is 
rarely excessive in degree, and the minimal 
effect on renal function is ideal for the severely 
hypertensive subject. The accompanying seda- 
tion, however, may make the neurologic assess- 
ment of the patient difficult. Therefore, in 
the presence of hypertensive encephalopathy or 
cerebrovascular disease it is wiser to use a short- 
acting ganglion-blocking agent like camphodium 
(Arfonad@) or parenteral pentolinium. 
GUANETHIDINE : CLINICAL EFFECTS 
In contrast to the gentle if insidious effects of 
reserpine, guanethidine is rough hewn, produc- 
ing extensive sympathetic blockade and conse- 
quently more obtrusive side effects. 
The onset of action is quite slow. It takes a 
few hours to achieve maximum blockade after 
TABLE 111 
Side Effects of Guanethidine 
A. Attributable to hypotensive action: 
1. Fatigue, weakness and lassitude (especially in 
morning or after exercise) 
2. Dizziness 
3. Syncopc 
4. Nitrogen retention 
B. Nonspecific : 
1. Diarrhea 
2. Fluid retention 
3. Depression 
4. Nasal stuffiness 
5. Parotid pain 
6. Failure of ejaculation 
7. Muscle tremors 
parenteral injection. Intestinal absorption is 
incomplete, and the excretion of its metabolites is 
prolonged, only 24 per cent appearing in the 
urine 24 hours after a single oral dose.21 There- 
fore, two to three days are required to achieve a 
steady response with oral dosage. The effect 
on the blood pressure, like that of other auto- 
nomic blocking agents, is evident mainly in the 
standing position. 
Guanethidine produces its hypotensive action 
by reducing both cardiac output and total 
peripheral resistance in recumbent position. 
There is also a small reduction in inulin and 
PAH clearances.22 On physical exertion the 
blood pressure may fall further in patients tak- 
ing large doses of guanethidine,23 almost cer- 
tainly because normal vasoconstriction fails in 
inactive vascular areas while dilation is occur- 
ring in the active muscles. The fall in pressure 
occurs in spite of an increase in cardiac output 
during exercise.24 
Hypotensioe Efects: The fall in blood pressure 
on standing is a frequent cause of difficulty. 
The standing blood pressure is lowest in the 
morning on arising”“2S at which time patients 
TABLE II 
Therapeutic Effect of Guanethidine in 11 Hypertensive Patients 
-Blood Pressures------- -_ 
(mm. Hg) 
Mean Dose 
,---p Recumbent -c_ ----Standing----------- (mg./day) 
A.M. P.M. A.M. P.M. 
Before treatment 190/114 171/122 202/121 199/122 
After treatment 166/104 181/112 138/ 95 1661110 60 
Effect -24/-10 +10/-10 -64/-26 -33/-12 
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frequently complain of fatigue, lassitude, and 
then may faint quite suddenly. Since the differ- 
ence between the standing and recumbent pres- 
sures decreases as the day progresses, this effect 
may be missed when the patient attends the 
physician’s ofice. It has further been shown 
that hypotensive effects of exercise are greater 
in the morning than later in the day.” The 
magnitude of the effect both on the recumbent 
and standing pressures varies considerably from 
one patient to another as does the dosage re- 
quired. A mean dose of 60 mg./day in a group 
of 11 hypertensives recording their blood pres- 
sures at home produced a mean reduction of 
34/10 mm. Hg recumbent and 68/17 mm. Hg 
standing in morning readings. By the evening 
there was a mean increase of 15/8 mm. Hg re- 
cumbent and 25/5 mm. Hg standing pressurezd 
(Table II). The cause of this loss of therapeutic 
effect during the day is unknown. 
Although they have similar effects on the 
blood pressure, there is no relationship between 
the sensitivity of the blood pressure to ganglion- 
blocking drugs and guanethidine, but little 
evidence has been seen for the development of 
tolerance with the latter. 
The chief disadvantage of guanethidine, 
therefore, is that in many patients it is impossible 
to maintain an adequate reduction in recumbent 
pressure without unbearable postural symptoms 
in the morning. Furthermore, if the pressure 
rises much during the day, the expected benefit 
from the drug will be limited to a very short 
period of time. 
Side Effects: In addition to its hypotensive 
effect, guanethidine produces certain nonspecific 
effects (Table III) ; diarrhea” ez3 sZ6 has been the 
most prominent. From our own experience 
and from a review of the literature, diarrhea 
appeared to occur whenever the dosage of the 
drug was high or was increased rapidly. Weight 
gain or edema has been observed,21 ,23~26 and 
mental depression has been reported, as have 
parotid pain, nasal stuffiness, failure of ejacula- 
tion and muscle tremors. The cause of these 
side effects is not understood, but they are read- 
ily reversible by reducing the dosage or with- 
drawing the drug. 
Clinical Application: At present the most 
powerful antihypertensive agents are the auto- 
nomic blocking agents. Of these guanethidine is 
undoubtedly the most effective in relation to its 
nonspecific side effects. This drug is, there- 
fore, required by most patients with severe 
hypertension. The gradual onset of action and 
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prolonged effect, however, make the drug un- 
suitable for use in emergency cases. 
Side effects can be minimized by increasing 
the dosage gradually: 12.5 mg./day is the best 
initial daily dose increased to 25, 50, 75, 100 
or 150 mg./day in weekly steps until the required 
effect is reached. If this gradual program is 
thought to be dangerously slow for the patient 
with severe disease, it is preferable to supple- 
ment it temporarily with a ganglion-blocking 
agent (mecamylamine) than to accelerate the 
regimen. The action of all blocking agents is 
variable; if an effective dose of the drug is to be 
used, inevitably occasions will arise when symp- 
toms of the excessive blockade are experienced, 
e.g., after an infection, unusual exercise, in hot 
humid weather or even after a large meal. To 
help the patient maintain an optimal therapeutic 
response to the drug, he should be made aware 
of the symptoms he may encounter and how to 
deal with them. 
In view of the inevitable fluctuations in pres- 
sure with autonomic blocking agents, they should 
be used with care in patients with advanced 
coronary or cerebrovascular diseases. How- 
ever, they are not necessarily contraindicated in 
these conditions when severe hypertension is 
present ; in fact, angina may be relieved as 
effective control of blood pressure is achieved.” 
SUMMARY 
Both reserpine and guanethidine appear to 
utilize the same fundamental pharmacological 
mode of action which leads to depletion of 
tissue catecholamines. 
Guanethidine produces effects on the blood 
pressure similar to those of the ganglion-blocking 
agents without the troublesome side effects. 
It is an extremely potent agent, however, and 
is likely to produce symptoms attributable to 
postural hypotension. 
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